Machina Capital S.A.S. Invests $2.27 Million in Cencora, Inc. $COR

Machina Capital S.A.S. bought a new position in Cencora, Inc. (NYSE:COR) in the second quarter, HoldingsChannel reports. The firm bought 7,579 shares of the company’s stock, valued at approximately $2,273,000.

A number of other large investors also recently bought and sold shares of the business. Atlantic Edge Private Wealth Management LLC boosted its holdings in Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after acquiring an additional 35 shares during the period. Obermeyer Wealth Partners boosted its holdings in Cencora by 1.3% during the 1st quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company’s stock valued at $758,000 after acquiring an additional 36 shares during the period. Grove Bank & Trust boosted its holdings in Cencora by 4.3% during the 2nd quarter. Grove Bank & Trust now owns 879 shares of the company’s stock valued at $264,000 after acquiring an additional 36 shares during the period. U.S. Capital Wealth Advisors LLC raised its position in Cencora by 0.4% during the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock valued at $2,563,000 after purchasing an additional 38 shares in the last quarter. Finally, Monument Capital Management raised its position in Cencora by 2.4% during the 2nd quarter. Monument Capital Management now owns 1,637 shares of the company’s stock valued at $491,000 after purchasing an additional 38 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Down 1.1%

Shares of NYSE:COR opened at $337.60 on Monday. The business’s 50-day moving average is $308.09 and its 200 day moving average is $297.19. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $350.46. The firm has a market capitalization of $65.45 billion, a P/E ratio of 34.73, a P/E/G ratio of 1.56 and a beta of 0.63. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company had revenue of $80.66 billion for the quarter, compared to analyst estimates of $80.34 billion. During the same period in the prior year, the company posted $3.34 EPS. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. On average, research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 15th. Cencora’s dividend payout ratio is currently 22.63%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on COR shares. Evercore ISI set a $340.00 target price on Cencora in a research report on Wednesday, October 8th. Wells Fargo & Company lifted their target price on Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research report on Wednesday, August 13th. Morgan Stanley set a $330.00 target price on Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Cencora in a research report on Thursday. Finally, Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $329.55.

Insider Activity

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the sale, the chief executive officer owned 37,940 shares in the company, valued at approximately $12,398,792. The trade was a 11.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the sale, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 41,544 shares of company stock worth $12,230,941 over the last ninety days. 10.80% of the stock is currently owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.